Minerva Neurosciences, Inc. (NASDAQ:NERV) seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s insomnia med Ambien in a phase 2b study. The Waltham, Massachusetts-based biotech is developing seltorexant with Janssen as an add-on treatment for major depressive disorder and insomnia disorder. While Ambien (zolpidem) activates the GABAA receptor to treat insomnia, seltorexant works by blocking the orexin-2 receptor. The orexin system promotes wakefulness and is believed to have a hand in excessive arousal in patients with insomnia as well as some patients with mood disorders.
Minerva Neurosciences, Inc. (NASDAQ:NERV), a Healthcare sector firm, traded 27.76 Million shares in last trading session with closing price of $5.93 per share. Stock value has moved between $4.06 – 12.89 in last one year. Analyst’s mean target price for Minerva Neurosciences, Inc. stock is $19.75 while analysts mean recommendation is 1.50. NERV stock EPS growth this year is -19.90%.
On last trading day, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares closed at $0.14 per share. SLS market capitalization is 3.46 with beta of 1.21. Analyst’s mean target price for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is $8.75 whereas analysts mean recommendation is 2.00. Its weekly performance is -12.36% while year to date (YTD) performance is -88.81%.
In last session Array BioPharma Inc. (NASDAQ:ARRY) traded 8.57 Million shares and was closed at $46.23. Analyst’s mean target price for ARRY is $32.40 while analysts mean recommendation is 1.60. Company is -1.74% away from its 52 week high and is moving 268.07% ahead of its 52 week low. ARRY Gross Margin is 92.40% and its return on assets is -24.50%. Array BioPharma Inc. (NASDAQ:ARRY) quarterly performance is 101.70% while its price to sale ratio is 43.11.
Histogenics Corporation (NASDAQ:HSGX), a Healthcare sector firm, traded 7.77 Million shares on last trading day with closing price of $0.19 per share. Stock value has moved between $0.08 – 3.17 in last one year. Analyst’s mean target price for Histogenics Corporation (NASDAQ:HSGX) is $5.00 while analysts mean recommendation is 3.00. HSGX EPS growth this year is 76.40%.